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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a disease characterized by poorly 
reversible airflow limitation of the airways that is usually progressive and associated with 
an abnormal inflammatory response in the lung1. The abnormal inflammatory response is 
usually triggered by smoking2, or other environmental irritant exposures3 which interact 
with genetic factors4, leading to both airway and systemic inflammation resulting in airway 
injury and lung damage. 
The term COPD is a descriptive term encompassing a heterogeneous subset of clinical 
syndromes, specifically chronic bronchitis, emphysema and asthma and it is now recognised 
that there is significant overlap between the previously described clinical syndromes. The 
term ‘overlap syndrome’ is often used to describe a patient with fixed airflow obstruction 
(COPD), but having some asthmatic features5.  Chronic bronchitis is clinically defined as a 
cough productive of sputum lasting at least three months for two consecutive years and 
emphysema is a pathological entity characterised by destruction of the lung parenchyma 
with resultant enlarged alveolar spaces and loss of alveolar walls6. 
Morbidity and mortality due to COPD are significant and there remains a significant unmet 
clinical need. Many acute medical admissions to hospital are due to exacerbations of COPD7 
and mortality can be high as many patients with an acute exacerbation of COPD may not 
fulfil the criteria for admission to intensive care8 and ward based management including 
non-invasive ventilation may not be appropriate in all cases due to intolerance or in the 
terminal stage of the disease9, 10. Globally, COPD is on the rise and currently it is ranked as 
the fifth largest disease to cause death worldwide11 and estimation by the World Health 
Organisation is that by 2020, it will be the third largest cause of mortality. Despite this 
significant level of morbidity, many of the management and prevention targets outlined in 
the 1998 Global strategy for the diagnosis, management and prevention of Obstructive 
pulmonary Disease (GOLD) have not been met12. A better understanding of the 
inflammatory pathophysiological mechanisms in COPD is essential to developing novel 
effective therapies. 
2. Pathogenesis 
The major risk factors for COPD are tobacco smoking; occupational dust exposure, 
industrial fumes, and indoor pollution from biomass cooking with inadequate ventilation in 
poor living conditions and all of these have been directly implicated in the abnormal 
inflammatory response in the airways13, 14. However, not all smokers get COPD, so clearly 
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there are genetic factors which define the ‘susceptible smoker’. The best characterised 
genetic susceptibility factor is homozygous deficiency of -1 antitrypsin15 but there are 
clearly other factors which are poorly understood. 
The pathophysiology of COPD involves inflammation of the proximal and peripheral 
airways and destruction of lung parenchyma with emphysema. The airway damage 
results in significant physiological derangement with expiratory airflow limitation and 
abnormal gas exchange16. Emphysema contributes to the airflow limitation by reducing 
the elastic recoil of the lung through parenchymal destruction, as well as by reducing the 
elastic load applied to the airways inflammation is present in smokers before airflow 
obstruction is evident with pulmonary function tests17.. Persistent and progressive 
inflammatory changes in the large and smaller airways are the hallmark of the disease 
process and once established, these changes persist even in ex-smokers18. The 
pathophysiology of COPD involves inflammation of the proximal and peripheral airways 
and destruction of lung parenchyma with emphysema19, 20.The airway damage results in 
significant physiological derangement with expiratory through destruction of alveolar 
attachments21. Inflammation of peripheral airways contributes to the airflow limitation by 
increasing the thickness of the airway wall which, together with fibrosis and smooth 
muscle hypertrophy, may cause airway narrowing. The presence of increased quantities 
of purulent sputum in the airways also contributes to airflow limitation22. Functionally, 
the decrement of FEV1 is due to both the small airways narrowing and mechanical effects 
of emphysema while the decrease in gas transfer arises from the parenchymal destruction 
of emphysema. Whilst the inflammatory changes are present in stable COPD, they 
become more evident in exacerbations of the disease23 and recurrent exacerbations can 
accelerate this process with progressive loss of lung function24. Recent data has also 
demonstrated systemic inflammation is also present in COPD, and there is a strong 
association of increased cardiopulmonary mortality in COPD patients with exaggerated 
systemic inflammatory markers25. COPD is associated with important comorbidities 
including cardiac failure, metabolic syndrome and the combination of these co-
morbidities combined with a systemic inflammatory response has led to the term of 
‘chronic systemic inflammatory syndrome’ 26.  
3. Stages of inflammation in COPD 
The precise immunological inflammatory mechanisms in COPD have not been totally 
elucidated but there is mounting evidence to suggest that there is a cascade of evolutionary 
events involved in the development of disease. Many of the steps in this cascade are similar 
to those proposed in other chronic inflammatory diseases27 such as rheumatoid arthritis, 
atherogenesis, multiple sclerosis, and systemic lupus erythematosus 28.  
On the basis of current evidence, it has been suggested that the immunological 
inflammatory / repair pathway in COPD comprise of three stages29. 
Stage 1: Initial response to the smoke and noxious stimuli 
The constant insult due to inhaled irritants to the airways kick starts both innate and 
adaptive immunological responses. The innate response is a non-selective response while 
the adaptive response is more selective to specific antigenic stimulation. The innate response 
results in a non-specific inflammatory response in the airways and lung parenchyma with 
recruitment and activation of inflammatory cells such as neutrophils and macrophages30. 
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Stage 2: T-cell proliferation 
There is migration of dendritic cells to regional lymph nodes with resultant significant 
proliferation of T-lymphocytes during this phase which results in the expression of pro-
inflammatory cytokines and interferon-Y positive T-lymphocytes which has a direct link 
with disease activity31. The role of tissue specific chemokines driving an ongoing 
inflammatory influx becomes more evident by this time32. 
Stage 3: Adaptive immune response 
The adaptive response of immunity is the hallmark of this step which leads to the 
dominance of CD8+ cytotoxic lymphocytes in all parts of the airways and lung 
parenchyma33. The function of these cells involves apoptosis and eventual tissue 
destruction34. However, the CD4 lymphocytes and B lymphocytes are also found 
abundantly in the airways of patients with COPD35, 36. 
4. Cellular inflammatory response in COPD 
The inflammatory process in COPD occurs due to a persistent airways insult (commonly 
tobacco smoke exposure) and is characterised by abnormal activation of both the innate and 
adaptive immune responses of the airway tract. The cells which have been most implicated 
in the pathogenesis of COPD have been the CD8+ T lymphocyte and the macrophage, 
however, other cells, in both the innate immune system and the adaptive immune response 
are also likely to have important roles, including neutrophils, airway epithelial cells, 
endothelial cells, eosinophil and fibroblasts37.  
Cells involved in inflammation in COPD (innate and adaptive immune response) 
CD8+ lymphocytes 
Macrophages 
Neutrophils 
CD4+ lymphocytes 
Epithelial cells 
Endothelial cells 
Eosinophil 
Fibroblasts 
Cytokines and chemokines of inflammation 
Interleukin 8(IL-8) 
Tumour necrosis factor (TNF-ǂ) 
Interleukin 6(IL-6) 
Leukotriene-B4 (LTB4) 
GRO alpha (GRO- ǂ) 
Interleukin 1(IL-1) 
Sampling the airway using induced sputum, has demonstrated an airway neutrophilia in 
patients with COPD, which is also seen in sputum samples of non-obstructed smokers, 
but to a lesser extent38. Bronchial biopsies demonstrate an infiltration of CD8+ T 
lymphocytes and recent data suggests reduced apoptosis of these CD8+ cells in the airway, 
which may explain one of the mechanisms of their persistence in the airway39. These CD8+ 
T lymphocytes infiltrate the lung and pulmonary vasculature and it has been 
hypothesised that this reflects an underlying auto-immune process specifically that lung 
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injury in COPD may occur due to an auto-antigen recognised by the CD8 cytotoxic T cells 
causing airway damage40, 41 
In the case of emphysema, alveolar macrophages have been implicated and in 
bronchoalveolar lavage samples, the numbers of activated macrophages are 5 to 10 fold 
higher than non-obstructed smokers 42. These macrophages also produce oxidants and pro-
inflammatory cytokines and proteases which collectively potentially drive lung 
parenchymal destruction43. 
Protease / anti-protease imbalance 
As a consequence of activated inflammatory cells in the airway and alveolar compartment, 
proteases including neutrophil elastase, cathepsins and matrix metalloproteinases (MMP) 
are released and have been implicated in the patho-physiology of COPD44. Bronchoalveolar 
lavage macrophages from patients with emphysema express more MMP-9 and MMP-1 than 
cells from control subjects, suggesting that these cells, rather than neutrophils, may be the 
major cellular source of these proteases45. The action of the proteases is inhibited by anti-
proteases like, -1antitrypsin (-AT), 1- anti-chymotrypsin, secretory leukocyte protease 
inhibitor (SLPI), and tissue inhibitors of metalloproteinases (TIMPs) 46. A decrease in anti-
protease activity is considered as a potential factor in airway wall and parenchymal 
destruction causing emphysema47. However, given that many smokers with airway 
inflammation do not develop COPD and those who do develop COPD have varying degrees 
of emphysematous change, the interaction between protease and anti-protease activity is 
likely to complex and heterogeneous48.  
Cytokine / chemokine response 
As a consequence of the abnormal cellular activation in the airway, pro-inflammatory 
cytokines including interleukin 8 (IL-8) and tumour necrosis factor (TNF-) are 
upregulated49. Both IL-8 and TNF promote neutrophil chemotaxis and activation of 
adhesion molecules. In parallel, a reduction of the anti-inflammatory cytokine IL-10 
promotes a pro-inflammatory environment50. Many of the pro-inflammatory abnormalities 
identified in induced sputum and lung biopsies of COPD patients persist even after 
smoking cessation51, suggesting that once the inflammatory process has been activated, and 
removal of the original inciting insult does not stop a progressive process. 
In COPD, the inflammatory process is also augmented by the important chemotactic 
mediators such as leukotriene-B4 (LTB4) and GRO alpha (GRO-). Both GRO- and IL8 
recruit neutrophils to the airway and IL8, TNF- and LBT4 are increased in the sputum of 
COPD patients52. Some patients show evidence of eosinophil recruitment to the airway and 
increased eosinophil basic proteins (eosinophil cationic proteins and eosinophil peroxidase) 
have been observed in induced sputum of COPD patients. This may reflect ‘overlap’ 
syndrome as described above, and sputum eosinophilia has been shown to predict a better 
response to steroid treatment in COPD53. 
Oxidative stress 
Increased oxidative stress has been suggested to be an important piece in the inflammatory 
jigsaw of chronic obstructive pulmonary disease54. Cigarette smoke causes increased 
oxidative stress55. Smoking produces exogenous stress to the epithelial cells of the airways 
due to the presence of harmful oxidants in the smoke. Endogenous stress occurs due to the 
inflammatory process56 provoked by the increased production of alveolar neutrophils and 
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macrophages and endogenous oxidants like, hydrogen peroxide, ethane, and isoprostane in 
the exhaled breath condensates from patients with COPD57. 
Oxidative stress may increase mucous secretion, enhance elastase activity and reduce 
activity of protease inhibitors58. Moreover, oxidative stress activates nuclear factor-B (NF-
B) which increase transcription of important  pro-inflammatory genes like, IL-8, Inducible 
nitric oxide synthase and cyclooxygenase (COX-2) are possible factors59. An increase in 
endothelial dysfunction of peripheral blood vessels together with haemostatic and 
coagulation markers have also been reported after inhalation of cigarette smoke and 
particulate matter, again supporting the profound systemic effects of inhaled tobacco 
smoke60. 
Systemic inflammation in COPD 
As well as an inflammatory response in the airways, chronic obstructive pulmonary disease 
is characterised by systemic inflammation61. Evidence exists to support the fact that the 
systemic inflammation is seen in stable COPD and when there is an exacerbation, systemic 
inflammatory markers get worse, 62, 63.  
The precise interaction between systemic inflammation and COPD pathogenesis is unclear. 
In smokers, increased serum levels of CRP relate to a higher risk of developing COPD64. As 
well as CRP, other serum biomarkers are elevated in COPD including fibrinogen, TNF-ǂ, IL-
6 and IL-8. In general, acute phase reactants are strongly induced by IL-6 or TNF-alpha 
cytokines65. Higher concentrations of these markers have been observed in the cases of 
severe COPD66. Plasma CRP and fibrinogen are acute phase proteins which are produced in 
the liver and are released in the bloodstream and fibrinogen is under the control of IL-6. 
Raised levels are present in the blood of stable COPD patients but significantly higher levels 
have been described during exacerbation of COPD which strongly suggest its systemic 
inflammatory link to airway obstruction67. This rise of plasma fibrinogen in patients with 
COPD can be of further clinical importance since it has been implicated in coronary heart 
disease68. An inverse relationship between systemic inflammatory biomarkers and 
pulmonary function tests (FEV1) has been described, which may be of a diagnostic value 
and helpful to determine prognosis69, 70.  
The concept of systemic inflammation in COPD is based upon the theory of ‘spill-over’71. 
According to this theory, pulmonary inflammation stimulates the haematopoietic system, 
releasing increased numbers of leucocytes and platelets into the bloodstream72, 73. Lung-
derived inflammatory cytokines and other mediators circulate in the bloodstream and then 
cause a systemic inflammatory effect74. However whilst systemic inflammation certainly co-
exists with lung inflammation, it has not been proven in studies using the surfactant 
marker-D (SP-D,) that the inflammatory mediators present in the systemic circulation are 
actually derived from the lung75.     
Obesity and the metabolic syndrome76 have been identified as risk factors for COPD, but, 
their relationship with inflammation and COPD needs further explanation77. Hormones 
including adiponectin and most notably leptin may have a role in mediating systemic 
inflammation. Leptin has effects on adipose tissue and on the hypothalamus to regulate 
food intake by satiety but it is also a T-cell modulator and influences inflammation. Leptin 
levels are influenced by IL-6 and lipopolysaccharide78. It is profoundly increased in the 
sputum of COPD patients and correlates with sputum CRP and TNF-ǂ levels79. Conversely, 
it is well known that cachexia in COPD is a marker of increased mortality and may be due to 
an increase in lipolysis due to persistent inflammation80.  Half of COPD patients die with 
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cardiovascular events in hospital and as the role of systemic inflammation in heart disease is 
proven, the relationship between COPD and ischaemic heart disease may be important81. It 
has been proposed that systemic inflammation in COPD affects the vascular endothelium 
causing arterial stiffness and atherosclerosis. The presence of increased CRP and circulating 
leukocytes in patients with COPD and cardiovascular events supports this theory 82. Many 
other inflammatory mediators including tissue factor, FVIIa83, and nitric oxide have been 
studied to explore involvement of the coagulation system and oxidative stress in causing 
systemic inflammation in COPD84, 85.  
Osteoporosis and osteopenia are important disease co-morbidities of COPD86. Reduced bone 
density, resulting in fractures in COPD patients is common and increases as the disease 
progresses87. This is very notable in patients with alpha antitrypsin-1 deficiency. A number 
of studies have suggested that systemic inflammation is implicated in reduced bone 
density88, 89. Bone remodelling due to increased osteoclastic activity may be related to 
systemic inflammation, skeletal muscle loss and reduced physical activity, poor nutritional 
status, hypovitaminosis D, nutritional calcium deficiency and glucocorticoid treatment90, 91.   
Comorbidities in COPD 
COPD has significant morbidity and mortality92. There are multiple extra-pulmonary 
manifestations, which are related to the disease and other systemic effects93, such as 
weight loss, muscle wasting, osteoporosis, cachexia, atherosclerosis and co-morbid 
associations such as congestive cardiac failure, depression & chronic fatigue, dementia 
and cancer.  More than 50% of deaths among COPD patients are from the cardiovascular 
causes94, 95. Chronic obstructive pulmonary disease progression not only has important 
physical effects but also has significant psychological morbidity66. Depression is common 
in COPD and correlates with reduced exercise tolerance, muscle weakness and fatigue97. 
Studies have demonstrated that as COPD gets worse, fatigue and depression leads to a 
decline in quality of life and ultimately a worse prognosis. TNF-ǂ has also been 
implicated in the depression seen in COPD patients and an association between systemic 
markers of inflammation and depression whilst modest, is statistically significant, in 
comparison to the other co-morbidities98.   
5. COPD and related co-morbidities 
Lung:  
Pneumonia 
Lung cancer 
Obstructive sleep apnoea 
Heart: 
Pulmonary hypertension 
Cor-pumonale 
Coronary heart disease 
Congestive cardiac failure 
CNS: 
Anxiety 
Depression 
Stroke 
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Musculo-skeletal: 
Peripheral muscle deconditioning 
Peripheral muscle wasting 
Steroid myopathy 
Osteoporosis and bone fractures 
Blood and circulation: 
Peripheral vascular disease 
Normocytic anaemia 
Metabolic and endocrine: 
Diabetes 
Metabolic syndrome 
Degenerative: 
Cognitive impairment 
Parkinson’s disease 
Miscellaneous: 
Arthritis 
Glaucoma 
Bowel and prostate cancer 
In summary, there is a consensus now that both airway and systemic inflammation play a 
key role in the pathogenesis of chronic obstructive pulmonary disease99, 100,  101.  The 
underlying mechanisms and interactions are likely to be complex and need better 
description which is an important future research goal102.  
6. Current treatment of COPD 
Whilst COPD is a complex disease, current treatments are largely symptomatic and do not 
significantly alter the natural disease progression103. Many countries have formulated their 
own guidelines and most national and international respiratory societies have taken 
initiatives to provide training and knowledge to their professionals and act as patient 
advocates104.  
Conventionally, COPD is treated with both pharmacological and non-pharmacological 
interventions105, 106. Smoking cessation, regular exercise, adequate nutritional support, 
weight reduction and pulmonary rehabilitation are the important non-pharmacological 
treatment modalities107. Bronchodilators, anti-cholinergic, thioxanthines, steroids and 
antibiotics for bacterial exacerbation and oxygen therapy are the medical therapeutic 
options108. Smoking cessation and long term home oxygen109 are the only two treatments 
which have been demonstrated to improve mortality110. The remaining treatments provide 
symptom control and some improvement in quality of life111.  Short and long acting beta 
adrenoceptor agonists have been the gold standard of airways disease in COPD and asthma, 
and in COPD112 there has been a move to the earlier introduction of long-acting 
bronchodilators, and it is probable that multiple combinations of long-acting bronchodilator 
therapies will become available113. 
Treatment of inflammation in COPD 
The concept of targeting inflammation to treat COPD has largely been neglected until 
relatively recently114The mainstay of current anti-inflammatory therapy is steroid therapy, 
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however it is now recognised that these drugs have a minimal effect in established COPD115. 
As stated above, there is a pressing need for a better understanding of the key patho-
physiological mechanisms in this disease to allow more targeted therapy. 
Steroids 
A number of clinical trials in COPD demonstrated that high dose inhaled steroid treatment 
had no effect in disease progression, measured by progressive loss of FEV1, however there 
was some improvement in disease specific quality of life116. Inhaled steroids reduce 
exacerbations in COPD and this has been demonstrated in a number of studies examining 
long-acting ǃ-agonists / inhaled steroid combination therapies117. Despite, the predominant 
neutrophilic and lymphocytic involvement of cells in the pathogenesis of COPD, the 
presence of some eosinophils118 in the airways of such patient have provoked a great interest 
in the non-invasive, easy and reproducible measurement of biomarkers such as the of 
fractional exhaled nitric oxide (FENO) to identify patients who may respond better to 
steroid therapy119, 120however FeNO is reduced by smoking   
Phosphodiesterase 4 (PDE4) inhibitors 
There are other therapies which have been investigated to target inflammation in 
COPD121. Roflumilast is the first selective PDE4 inhibitor which has recently been licensed 
for COPD in Europe and America. It has been advocated in subjects with frequent 
exacerbations and symptomatic severe COPD patients with productive cough122. 
Roflumilast is an oral preparation which inhibits pulmonary inflammation through the 
selective inhibition of the iso-enzyme PDE4, which hydrolyses cyclic AMP123, which is 
expressed in structural cells of the lung such as, smooth muscle cells, airway epithelium 
and inflammatory cells such as neutrophils, lymphocytes or macrophages124. Despite the 
concerns regarding dose dependant side effects such as headache, nausea and 
diarrhoea125, it may offer some benefit in COPD patients with frequent exacerbations. 
Recent data have demonstrated that the use of roflumilast decreased the exacerbations 
and the need for adjuvant steroid therapy. Its use showed improvement in pulmonary 
function tests and when compared with the placebo, it showed improvement in functional 
capacity126, 127. Further longitudinal studies are warranted to measure the real benefit and 
effectiveness. However the clinical use of roflumilast has been encouraging so far in 
reducing exacerbations and improving lung function128. 
Novel treatment strategies for COPD 
With better understanding of the pathophysiology of COPD disease process and recognition 
of inflammation as an important feature,  it is anticipated that disease modifying therapy for 
COPD129 targeting pulmonary and systemic inflammation, will prove effective. There are a 
number of specific therapeutic targets against the influx of inflammatory cells into the 
lung130. including inhibitors of p38 mitogen-activated protein kinase (MAPK), nuclear 
factor-κB (NF-κB), and phosphoinositide-3-kinase (PI3K) 131. There is also a search for 
inhibitors of proteinases and matrix metalloproteinases (MMPs) which could prevent lung 
destruction and emphysema. The immunomodulatory role of macrolides is also one of the 
potential novel treatments for COPD132. 
Cytokines and chemokines inhibitors 
TNF-ǂ TNF-ǂ plays a key role in COPD and acts as a catalyst for chemokine interleukin-8 
(IL-8). Infliximab is a monoclonal antibody which neutralizes TNF-ǂ by binding it. Its role 
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has been evaluated in COPD133 but its use has failed to show any change in sputum 
neutrophils, FEV1, FEV1/FVC or IL-6134. There is also significant toxicity and cost issues and 
further attempts to use it in COPD have been halted135.  
Antibody against human IL-8 
A fully humanised monoclonal IgG2 antibody directed against human IL-8 (ABX-IL8) blocks 
binding to IL-8 receptors on neutrophils and neutralizes IL-8–mediated neutrophil 
activation in vitro136. It has been shown that pretreatment of sputum supernatant of 20 
patients with COPD with an anti–IL-8 antibody led to a concentration-dependent inhibition 
of neutrophil chemotaxis.  Moreover, ABX-IL8 is proposed to block IL-8–induced neutrophil 
activation and degranulation, preventing release of neutrophil elastase137.However in a 
clinical trial, whilst well tolerated and shown to be beneficial in reducing dyspnoea, there 
was no real added benefits were noted in secondary outcomes (lung function, health status 
and inflammatory markers) 138.  
CXCL1, CXCL8 receptor antagonists 
CXCL1 (GRO-ǂ) is produced by structural and inflammatory cells and is chemotactic for 
neutrophils139. Using agents which are CXCL1 and CXCL8 (IL8) receptor antagonists blocks 
the neutrophilic inflammatory response in the lungs and may help to control COPD140 and 
clinical trial data is awaited 
CCL2 (MCP-1) and CCR2 antagonists 
Bronchoalveolar lavage from patients with COPD contains increased MCP-1 (CCL2) in 
comparison to healthy non-smokers141 and it has also been postulated that in COPD, the 
MCP-1 receptor, CCR2, shows increased expression. These findings relate to disease severity 
and FEV1. Therefore targeting of CCL2 and its receptor could provide potentially potent 
and novel anti-inflammatory agents142. The study of such products in humans is in the early 
phase and clinical preparations are probably a long way off currently143. 
5-Leukotriene B4 / Lipoxygenase inhibitors 
Leukotriene B4 (LTB4), a pro-inflammatory derivative of arachidonic acid, is both a 
chemoattractant and activator of neutrophils and may be important in COPD144. LTB4 is 
synthesized by neutrophils and alveolar macrophages, where the conversion of arachidonic 
acid to the intermediate compound 5-hydroperoxyeicosatetraenoic acid requires both the 
enzyme 5-lipoxygenase (5-LO) and 5-lipoxygenase activating protein (FLAP). In a 
preliminary double-blind, randomized, placebo-controlled trial the effects of the FLAP 
antagonist, BAYx1005, on sputum LTB4 and myeloperoxidase (a marker of sputum 
neutrophil number and activation) concentrations, and on the chemotactic activity of the 
secretions in patients with COPD and chronic bronchitis was studied145. A modest but 
significant reduction in sputum LTB4 concentrations in the patients in this trial was 
observed. However, the reductions in LTB4 concentration were comparable in magnitude to 
those seen during the resolution of purulent exacerbations of chronic bronchitis.  This study 
have established that a leukotriene synthesis inhibitor may affect neutrophilic bronchial 
inflammation in patients with stable COPD and chronic bronchitis, and that this class of 
drug merits further investigation in a larger number of patients. Another Possible way to 
inhibit leukotriene synthesis pathway is to target is 5-lipoxygenase inhibition146.  The 
potential clinical benefits of both of these approaches remain under investigation147. 
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Anti-oxidants including N-Acetylcysteine 
N-Acetylcysteine is an anti-oxidant which is most commonly used in paracetamol overdose. 
It targets oxidative stress and causes activation of anti-proteases and reduces expression of 
IL-8 and TNF-ǂ 148. Recent data demonstrated an improvement in vital capacity and 
inspiratory capacity of patients with COPD in an ICU setting149. NAC treatment of patients 
with stable, moderate-to-severe COPD has a beneficial effect on physical performance, 
probably due to a reduction in air trapping150 NAC probably exhibits an anti-inflammatory 
effect by influencing neutrophils and macrophage function151.  
p38 mitogen-activated protein kinase (MAPK) inhibitors 
p38 MAPK inhibitors are another novel drug strategy proposed for targeting inflammation 
in COPD152. The p38 MAPK pathway is activated by stress and it regulates a wide variety of 
inflammatory cytokines including IL-8, TNF-ǂ and MMPs153. Corticosteroids partially 
suppress cytokine production by COPD alveolar macrophages 154, 155 but p38 MAPK 
activation in alveolar macrophages is corticosteroid insensitive. One study investigated the 
dose-sparing and efficacy-enhancing effects of combined treatment with a corticosteroid and 
a p38 MAPK inhibitor, and showed the combination synergistically enhances the anti-
inflammatory effects on cytokine production by alveolar macrophages in COPD patients 
and controls156. Another study has demonstrated that SB-681323 is a potent p38 MAPK 
inhibitor that potentially suppresses inflammation in COPD157.  But further clinical trials 
with this class of molecule are starting and are eagerly awaited.   
Nuclear factor-κB (NF-κB) inhibitors 
Nuclear factor-κB (NF-κB) has been implicated in inflammation in COPD by causing 
propagation of cytokines and neutrophils158. Therefore, this pathway has been targeted to 
overcome inflammation and airways injury in COPD patients. One approach is to inhibit the 
IκB kinase (IKK) using glucocorticoids, such as dexamethasone or prednisolone which 
downregulates the pro-inflammation159. Experiments have also been performed using 
resveratrol, one of the flavonoids naturally occurring in red wine. It inhibits this pathway of 
inflammation160 however, there is no evidence of clinical benefit currently. 
Phosphoinositide 3-kinases (PI3K) inhibitors 
The components of the PI3K pathway play a crucial role in the expression and activation of 
inflammatory mediators, inflammatory cell recruitment, immune cell function, airway 
remodelling and corticosteroid insensitivity in COPD and asthma161.Targeting this pathway 
has a potential therapeutic role and this may be one of the actions of theophylline652 The 
idea for development of PI3K inhibitors would be to ensure greater efficacy in severe 
steroid-insensitive asthma and COPD where corticosteroids are of limited163 with a better 
side effect profile. 
7. Anti-proteinases 
Neutrophil elastase inhibitors 
For nearly two decades, there has been a pursuit to find safe oral inhibitors of neutrophil 
elastase. Many of the compounds developed have had poor pharmacokinetics and a low 
therapeutic index. Tripeptidyl trifluoromethyl ketones were the first developed with an 
improved profile but they have not been fully optimized for oral use yet164. Targeting 
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neutrophil elastase may be very useful in COPD since it can cause direct activation of 
MMPs such as MMP-9, which play a crucial role in airway inflammation165. Recent work 
on the relatively newer compounds like Sivelestat sodium hydrate has not proved to be 
very encouraging166.    
Matrix metalloproteinases (MMPs) inhibitors 
MMPs are a major class of proteolytic enzymes potentially involved in COPD. 
Bronchoalveolar lavage of patients with emphysema shows high levels of MMP-1 and 
MMP-9167. Drugs such as BMS-561392 and gw3333 which could inhibit the MMPs and TNF-
ǂ are in the pre-clinical stage. Their development and potential efficacy in targeting 
inflammation in COPD has yet to be established168. 
HDAC modifiers 
There are 11 classic human HDACs that regulate histone acetylatio169. HDAC2 is involved in 
suppression of NF-κB–mediated inflammatory gene expression by corticosteroids170 and 
HDAC2 mRNA and protein expression is significantly reduced in tissue specimens of the 
peripheral lung and in alveolar macrophages from patients with COPD171. This speculated 
link may have therapeutic implications, because reductions in HDAC activity may be 
reversible. Theophylline is an activator of HDAC157, and there is evidence to suggest that 
low concentrations of theophylline completely restore HDAC activity in alveolar 
macrophages from patients with COPD, with reduced production of inflammatory 
cytokines and restoration of responsiveness to corticosteroids172. It has been reported that 
theophylline173 and PI3K inhibitor (LY294002) have a similar effect in lung macrophage cells, 
increasing HDAC2 expression and re-sensitizing the cells to steroids. Whether this is a 
mechanism of the therapeutic action of theophylline in COPD is not known.  
Macrolides 
The hallmark of COPD is the airways inflammation which is primarily neutrophilic in 
nature and low grade neutrophilic inflammation is often persistent174. Treatment with 
macrolides has been shown to reduce the number of neutrophils and the levels of 
interleukin-8 (IL-8) protein in bronchoalveolar lavage fluid in COPD175. The mechanisms by 
which macrolides exert a beneficial effect on chronic inflammatory airway disease are 
thought to be independent of their antibiotic effects but rather due their anti-inflammatory 
effects176, through reducing lower airway bacterial colonization may also be beneficial177 
Macrolides in COPD decrease neutrophil counts and inflammatory markers and reduce the 
number of exacerbations178. The role of regular macrolides in COPD179 needs to be defined 
more clearly, and there remain concerns about widespread use of these drugs particularly 
with regard to antibiotic resistance and superadded infections like MRSA and C.difficile180.    
Non-pharmacological treatments – novel strategies 
Non-pharmacological treatments will remain important in the future management of COPD 
and will continue to involve more integrated care181. There is compelling evidence of the 
role of systemic inflammation in decreasing muscle mass, weakness and loss of function in 
COPD patients182and tests to detect early markers of muscle involvement may be clinically 
beneficial to target patients of greatest risk of losing muscle mass with early rehabilitation 
interventions183. Targeting patients with multiple co-morbidities and provision of early 
pulmonary rehabilitation and physiotherapy can have a major impact on improving 
morbidity and decreasing mortality184. Identifying which smokers are at risk of 
www.intechopen.com
Inflammation, Chronic Diseases and Cancer –  
Cell and Molecular Biology, Immunology and Clinical Bases 
 
344 
development of COPD and which patients will develop more progressive disease may also 
be important advances in the future185, 186, 187.  
8. Summary 
Chronic obstructive pulmonary disease (COPD) is a disease characterized by poorly 
reversible airflow limitation which is usually progressive and associated with an abnormal 
inflammatory response in the lung. Cigarette smoking is the major risk factor responsible for 
the development of COPD, however other environmental exposures, such as combustion of 
biomass fuels, are major causes in certain countries. A decade since the introduction of the 
Global strategy for the diagnosis, management and prevention of Obstructive pulmonary 
Disease (GOLD), the incidence of COPD continues to rise and the World Health 
Organisation and the World Bank predict that by the 2020, it will be the third leading cause 
of mortality in the world.  
The term chronic obstructive pulmonary disease is a descriptive term encompassing a 
heterogeneous subset of clinical syndromes, specifically chronic bronchitis, emphysema 
and asthma and it is now recognised that there is significant overlap between the 
previously described clinical syndromes. The term ‘overlap syndrome’ is often used to 
describe a patient with fixed airflow obstruction (COPD), but having some asthmatic 
features.  Chronic bronchitis is clinically defined as a cough productive of sputum lasting 
at least three months for two consecutive years and emphysema is a pathological entity 
characterised by destruction of the lung parenchyma with resultant enlarged alveolar 
spaces and loss of alveolar walls. 
The patho-physiology of COPD involves inflammation of the proximal and peripheral airways 
and destruction of lung parenchyma with emphysema. The airway damage results in 
significant physiological derangement with expiratory airflow limitation and abnormal gas 
exchange. Emphysema contributes to the airflow limitation by reducing the elastic recoil of the 
lung through parenchymal destruction, as well as by reducing the elastic load applied to the 
airways through destruction of alveolar attachments. Inflammation of peripheral airways 
contributes to the airflow limitation by increasing the thickness of the airway wall which, 
together with fibrosis and smooth muscle hypertrophy, may cause airway narrowing.  
The inflammatory process in COPD usually starts with a persistent airways insult 
(commonly tobacco smoke exposure) which leads to abnormal activation of both the innate 
and adaptive immune responses of the airway tract. Pathologically, epithelial squamous cell 
metaplasia, goblet cell hyperplasia, parenchymal destruction (emphysema) and small 
airway are all consequences of this persistent inflammatory environment. Both, innate and 
adaptive immune responses are involved in the inflammatory process in COPD. There is 
evidence that airways inflammation is present in smokers before airflow obstruction is 
evident with pulmonary function tests. The cells which have been mostly implicated in this 
inflammatory process CD8+ T lymphocytes and macrophages which through the production 
of LTB4, TNF-ǂ, IL-8, GRO- recruit neutrophils to the airway, with resultant injury. 
Increased neutrophils are seen in bronchoalveolar lavage and induced sputum of the 
patients with COPD compared to smokers without airflow obstruction. Neutrophil 
myeloperoxidase and human neutrophil lectin are also elevated consistent with neutrophil 
activation and degranulation. Some patients show evidence of eosinophil recruitment to the 
airway and increased eosinophil basic proteins (eosinophil cationic proteins and eosinophil 
peroxidase) have been observed in induced sputum of COPD patients. This may reflect 
‘overlap’ syndrome as described above, and sputum eosinophilia has been shown to predict 
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a better response to steroid treatment in COPD. Exacerbations are significant events in 
patients with COPD as they cause increased breathlessness and purulent sputum 
production. In patients with frequent exacerbations, there is accelerated lung function 
decline, as a consequence of augmented inflammation and injury during exacerbations. 
Bronchial biopsies in COPD have shown infiltration of mononuclear cells and CD8+ T 
lymphocytes. Macrophages are activated by cigarette smoke and other inhaled irritants and 
may play an important role in driving the inflammatory process in COPD through the 
release of neutrophil chemotactic factors as well as proteolytic enzymes. More recently, it 
has been suggested that COPD may represent an ‘auto-immune’ disease, with failure to 
regulate the adaptive response to auto-antigens produced as a consequence of tobacco 
smoke exposure. A subtype of regulatory CD4+ T-cells expressing CD25 (Tregs) are 
upregulated in COPD, which supports an auto-immune aetiology. 
Protease / anti-protease imbalance excessive oxidative stress have also been linked to 
progressive airway injury in COPD. Neutrophil elastase, cathepsins and matrix 
metalloproteinases have all been implicated in the patho-physiology of COPD. 
Bronchoalveolar lavage macrophages from patients with emphysema express more MMP-9 
and MMP-1 than cells from control subjects in COPD, suggesting that these cells, rather than 
neutrophils, may be the major cellular source. There is also evidence for increased oxidative 
stress in COPD, evidenced by an increase in oxidized or nitrated proteins and peroxidised 
polyunsaturated fatty acids and their degradation products. Increase in endothelial 
dysfunction of peripheral blood vessels together with haemostatic and coagulation markers 
have also been reported after inhalation of cigarette smoke and particulate matter, again 
supporting the profound systemic effects of inhaled tobacco smoke.  
There is growing evidence to suggest that as well as an inflammatory response in the 
airways, chronic obstructive pulmonary disease is characterised by systemic inflammation. 
Recent evidence has demonstrated systemic ‘spill-over’ of this pulmonary inflammation 
with evidence of elevated systemic inflammatory markers, pro-inflammatory cytokines and 
lipopolysaccharide binding protein. 
Systemic manifestations of COPD may significantly affect patients’ quality of life and 
prognosis of the disease. It has been well recognised that systemic effects may be related to 
systemic inflammation in COPD. COPD is associated with cachexia, weight loss, 
osteoporosis, muscle wasting, heart failure, atherosclerosis, dementia, depression, and 
cancer and these extra- pulmonary manifestations of COPD account for much of the 
morbidity and mortality in COPD patients. Depression is also a major co-morbidity in 
COPD and patients with more systemic inflammation as well as more depression or fatigue 
have been shown to be less physically active and more exercise intolerant. There is evidence 
to suggest that certain age related conditions like, arthritis, Parkinson’s disease and cancer 
of the prostate and bowel have links with COPD. The risk of developing arthritis, anaemia 
and glaucoma increases in COPD patients with growing age.  
Current anti-inflammatory therapies, particularly steroid therapy, have a minimal effect in 
established COPD. There is a significant need for a better understanding of the key patho-
physiological mechanisms in this disease to allow more targeted therapy. Novel 
pharmacological strategies are still in the developmental stage. Cytokine and chemokine 
inhibitors, for example antibodies against human IL-8, CXCL1, CXCL8 antagonists, CCL2, 
CCR2, lipoxygenase and LB4 inhibitors have shown some promise but there remain issues 
around safety and efficacy and cost effectiveness. The role of anti-oxidants, MAPK-
inhibitors and PI3k inhibitors is still under investigation. The use of macrolides has been the 
focus of recent attention and recent data has suggested a role in exacerbation prevention.  
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